Microsatellite Instability (MSI)

This test can help in choosing the most appropriate treatment and in further personalized cancer treatment. MSI is most commonly found in colon cancer and endometrial cancer. MSI has also been observed in cervical cancer, gastric cancer, glioblastoma, melanoma, ovarian cancer and prostate cancer.

The MSI assay:
  • Determines the prognosis in patients with stage II colorectal cancer (CLC).
  • Identifies patients with an increased likelihood of developing Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome).
  • Assists in the selection of patients with an indication for ColonAIQ.
  • Helps predict 5-FU therapy.
  • Predicts the patient's response to immunotherapy.

CancerMSI PrevelanceHistology
Breast<%1, unless occuring in young women with HNPCC
Cervical5%Advanced Cancers
Colorectal Cancer15%All Cancers
EndometrialUp to 33%40% of endometrioid tumours and 2% of serous tumours
Gastric15%All Cancers
Glioma0-33%Controversial dat. Pediatric, young adults
Head and Neck CancerNone
Lung Cancer<1%
Melanoma2-77%Inconsistent data
Ovarian10%All Cancers
Pancreatic and Periampullar1% in sporadic PDAC, 10% in cancers of periampullary areaAll cancers
Prostate CancerUp to 12%Advanced stage cancers
Renal cell carcinomaNone
Sebaceous skin tumours25%All Cancers
Thyroid 1%All Cancers

MSI Assay Specifications

Instabilities at microsatellite locations that are cancer-associated throughout the genome have been linked to a better response to immunotherapy. A Microsatellite Instability High (MSI-H) status can occur when the DNA Mismatch Repair (MMR) system fails to work appropriately.

Genomic DNA is extracted from the tumor tissue after microscopic observation and macro-dissection. Next-generation sequencing-based assay using 76 markers to assess Microsatellite Instability (MSI) status in both tumor-only and tumor-normal samples utilizing Ion Ampliseq technology.

Sequencing is carried out using the Next Generation Sequencing platform Ion Gene Studio S5 Prime System (Thermo Fisher Scientific). The test provides results for individual microsatellites and generates an MSI score. Α sample is considered positive if the MSI score is >30.

For patients where their response to immunotherapy must be investigated exclusively, the Immune Response test is recommended, which includes the three biomarkers for predicting response to immunotherapy TMB, MSI & PD L1


Frequently Asked Questions

What types of cancer does it cover?

The test covers all types of cancer and helps predict patients’ response to immunotherapy. MSI is most commonly found in colon cancer and endometrial cancer. MSI has also been observed in cervical cancer, gastric cancer, glioblastoma, melanoma, ovarian cancer and prostate cancer.

In how many days are the results delivered?

Results are delivered within 7 business days.

What type of sample is required for the test?

A paraffin block containing the tumor tissue or unstained paraffin slides.

Is the test covered by any public/private insurance?

For cost coverage and related information, please click here for the Genekor secretariat.

How do I make the payment for the test?

Payment can be made by bank transfer or debit/credit card

How I send the sample and receive the results?

Regarding the receipt of the sample, please contact the secretariat. The results are shared with your doctor and with you via email.

How to order the test?

Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.


*To complete the test, you are required to complete and send the Consent form that you will find on the link below.

If you want to send us your sample, please contact us in order to arrange all procedures.

*For more information on scientific content please contact: